Fig. 1From: Final results from IMPROVE: a randomized, controlled, open-label, two-arm, cross-over phase IV study to determine patients’ preference for everolimus in combination with exemestane or capecitabine in combination with bevacizumab in advanced HR-positive, HER2-negative breast cancerOverall Study Design. Duration of follow-up: ≥24 months, until death or end of study. R = randomization; PD = progressive disease; QoL = quality of lifeBack to article page